Allergan Announces Phase 3 Results for Rapastinel as an Adjunctive Treatment of Major Depressive Disorder (MDD)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. GOOGL
6. APGE
7. ABBV
8. USO
9. MSFT
10. IBM

Go back to Allergan Announces Phase 3 Results for Rapastinel as an Adjunctive Treatment of Major Depressive Disorder (MDD)

Appaloosa Issues Statement Regarding Allergan's (AGN) Failed Anti-Depression Study, Seeks Independent Chairman

March 7, 2019 10:56 AM EST

Appaloosa LP today issued a statement in response to Allergan plcs (NYSE: AGN) (Allergan) March 6, 2019 announcement that its drug, Rapastinel, failed a late stage study for treatment of major depressive disorder:

Yesterdays announcement that Allergans marquee pipeline drug, Rapastinel, had... More